Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluforsen (QR-010) in homozygous ΔF508 cystic fibrosis
NCT02532764Phase 2Completed
- Sponsor
- ProQR Therapeutics
- Start
- Jun 2015
- Primary completion
- Sep 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 10
01
Overview
A Phase 2 trial of eluforsen in cystic fibrosis (CF), sponsored by ProQR Therapeutics. Started Jun 2015; status: completed.
02
Drugs
eluforsen
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02532764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532764.